💸 The Tape

For a decade, cannabis M&A has been a genre of fiction: the deals get announced, the synergy slides get built, and then Pennsylvania's dispensary cap or someone's balance sheet quietly kills it in the fine print. That era is ending, and not because operators suddenly learned to love each other. It's ending because the federal structure of the industry changed in April, and every combination now has to be drawn against a map that didn't exist five months ago.

The fault line nobody can ignore

Since April 22, 2026, state-licensed medical cannabis sits in Schedule III and is free of Section 280E. Adult-use cannabis is still Schedule I, still taxed on gross profit, and still waiting on ALJ Derek Julius, who closed the evidentiary record in late August and will send his recommendation to DEA Administrator Terry Cole on his own schedule. That's the binary hanging over every deal: either adult-use follows medical into Schedule III and everyone gets a stock currency, or it doesn't and medical-only vehicles trade at a permanent premium while levered mixed-use operators get squeezed.

Trulieve saw the fault line first and jumped across it. On June 3 it deconsolidated its mixed-use markets (Arizona, Connecticut, Maryland, Ohio, 34 stores) into a sidecar called Harvest, controlled by a third-party investor while Trulieve keeps 90% of the economics. One week later it was ringing the bell on the NYSE — the first plant-touching U.S. operator to get there. The consolidated company is now 207 medical-only dispensaries across Florida, Georgia, Pennsylvania and West Virginia, with conditional licenses in Alabama and Texas, $325 million of cash against $289 million of debt, and a 36% EBITDA margin.

That structure — a listed medical-only acquirer with a mixed-use sidecar that absorbs adult-use assets — is the template every deal below has to be measured against.

The scoreboard

Balance sheets separate the buyers from the bought. Trulieve is net cash. Green Thumb has $284 million of cash against $283 million of debt and is spending it on buybacks. Verano refinanced to 2029 and sits near 1x leverage. Cresco is around 1.6x, with a departing CFO and a line in its earnings release about one-time costs for "acquisitions and uplisting preparedness" that reads like a company mid-process. Curaleaf carries $612 million of debt and is busy launching a hostile bid for Aurora Cannabis, which tells you where management's head is. Ascend and TerrAscend are in the low-2x range. And then there's Vireo, sitting on $123 million of cash, which has bought roughly a dozen companies in eighteen months and is on its way to 270 dispensaries — the largest retail footprint in the country.

The pairings that actually work

Trulieve + Good Day Farm. This is the cleanest deal on the board and it isn't close. Good Day runs a million square feet of production and 60-plus dispensaries across Arkansas, Mississippi, Missouri and Louisiana, where it holds one of only two state cultivation licenses. Three of those four states are medical-only, which means they're Schedule III-clean and can be consolidated straight into the NYSE entity with zero geographic overlap. Missouri, which is adult-use, goes to Harvest — and that conveniently solves Good Day's problem of being tied to more than a quarter of Missouri's dispensaries in a state with a 10% ownership cap. Add Good Day's deep Texas political ties to Trulieve's conditional Texas license and you have the Southern medical bloc, built by the only company that can pay in listed medical paper.

Story Cannabis + Harvest. Call it the Vedadi reunion. Jason Vedadi built the original Harvest, sold it to Trulieve for $2.1 billion, and then built Story in Arizona, Maryland, Ohio, Georgia and Louisiana. Trulieve's Harvest sidecar is Arizona, Connecticut, Maryland and Ohio. Arizona has no ownership caps and merges cleanly; Maryland and Ohio require divestitures down to the four- and eight-store caps, which is fine because Vireo and Green Thumb are both shopping for exactly that kind of single-state retail. Story's Georgia medical folds into Trulieve's Georgia. And Harvest — currently controlled by a passive investor with no operating scale — gets an operator who has done this before. Vedadi gets units that convert into TRLV once the exchange permits it. Everyone gets currency, nobody breaks the ring-fence.

Cresco + TerrAscend. The one Northeast public-to-public deal that doesn't die on a state cap. Cresco has no New Jersey; TerrAscend's New Jersey is its crown jewel. Cresco exited Maryland; TerrAscend has a full Maryland vertical. TerrAscend already exited Michigan, removing the market that would have poisoned everything. Pennsylvania is the collision — both are at or near the 18-store cap — so call it eight to ten stores and a grower-processor to divest. The prize is Cresco's brand portfolio flowing through TerrAscend's NJ/MD wholesale channel at 54% gross margins. Combined leverage lands around 2.3x, both are prepping uplistings.

The pairings that don't

Green Thumb + Verano is the deal everyone will pitch and the worst one on the board: both at the Illinois ten-store cap, both at the Pennsylvania cap, both holding New Jersey verticals under the one-per-class rule, both capped in Maryland, Ohio and Massachusetts. You'd divest forty-plus stores to close. The same logic kills Cresco + Ascend and Ascend + TerrAscend.

And Vireo isn't a dance partner. It's the dance floor.

What changes if the ALJ finishes the job

Everything above assumes the current split-scheduling world persists. If DEA extends Schedule III to adult-use in the next two quarters, the board gets reshuffled in three ways.

First, Trulieve's moat shrinks. The Harvest sidecar exists because the NYSE won't consolidate Schedule I revenue; once adult-use is Schedule III, Harvest comes back in-house, Trulieve becomes a bigger but more ordinary MSO, and the medical-only premium that makes it the sector's sole acquirer of record starts to compress. The Southern bloc still makes sense — Good Day's states are medical either way — but the exclusivity of Trulieve's currency disappears.

Second, the Northeast reopens. Green Thumb, Cresco, Verano and Ascend all get 280E relief on their adult-use markets overnight, uplistings that are currently "in preparation" get filed within weeks, and suddenly four companies have listed paper and cash flow they didn't have before. Cresco + TerrAscend accelerates rather than stalls, and Green Thumb goes from patient buyback machine to a buyer with a real reason to spend.

Third, the middle of the table stops being distressed. Levered mixed-use operators trading at 4x EBITDA because of tax overhang get re-rated, Vireo's all-stock-at-4x playbook loses its sellers, and the forced consolidation this piece is built on becomes optional consolidation — slower, pricier, and with far more bidders per asset.

In other words: in the split world, two structures win and everyone else scrambles for a chair. In the fully rescheduled world, the chairs multiply, the music keeps playing, and the winners are whoever files their uplisting first. Either way, the next twelve months could decide the industry's seating chart for the next decade.

📈 Dog Walkers

$CURLF ( ▲ 2.25% ) Responds

Aurora Cannabis told shareholders Monday to reject Curaleaf's hostile bid as inadequate. Curaleaf's reply landed within hours, and it didn't bother with diplomacy.

The core of Boris Jordan's counterpunch is a single question: if management's plan is worth more than US$4.00 a share, show the evidence. Curaleaf's answer to its own question is Aurora's guidance, which calls for fiscal 2027 revenue to fall back to roughly fiscal 2025 levels with adjusted EBITDA dropping sharply from the record just posted. Operating cash flow went negative in the June quarter. That, Jordan argues, isn't a company at an inflection point — it's a company going backwards while calling it a transformation.

The sharpest line is about the ATM program. Aurora's board approved selling shares at average prices of US$3.57 during fiscal 2026 and US$3.09 in the June quarter — both well below the US$4.00 it now says undervalues the business. In banker terms: you can't sell your own stock at $3.09 on Tuesday and call $4.00 a lowball on Wednesday. Curaleaf also tallies $398 million raised through equity issuances since September 2020, which is its way of reframing Aurora's "debt-free balance sheet" as something shareholders paid for one dilutive raise at a time.

On the numbers, Curaleaf's math is that the offer is a 45% premium to the unaffected price — the 63rd percentile of Canadian M&A premiums over the past decade — and 110% excluding Aurora's cash. The implied multiple, by Curaleaf's count, is 12.0x calendar 2026 EBITDA, roughly 68% above Canadian peers. The much-criticized US$5.00 cap, it argues, is an 82% headline premium and sits in the 92nd percentile of Canadian deal premiums. And in a nice bit of history, Curaleaf points out the cap structure is one Aurora itself used in its own hostile bidding days.

There's a governance jab too: seven consecutive years of "non-recurring" restructuring charges, ineffective inventory controls flagged by auditors every year since fiscal 2020, and KPMG's resignation in April 2024. Jordan's not-so-subtle conclusion is that management is protecting its own seats, noting Aurora has never once presented a counteroffer.

What it means

This is a fight over which multiple you believe. Aurora says look at the sum of the parts — cash, EU-GMP capacity, a growing international medical book. Curaleaf says look at the forward EBITDA — shrinking — and the market price, which the board itself was happy to sell into. Both have a point, and both are conveniently choosing the denominator that flatters them.

$OGI ( ▲ 0.85% ) Investor Sesh

Organigram Global (NASDAQ: OGI) (TSX: OGI) has opened registration for its 2026 OG Investor Session, a video presentation premiering September 30 at 4:00 p.m. ET. It's the company's second digital investor day, and the first since a wholesale reshuffle at the top.

That's the real story here. Since the last session, Organigram has installed a new leadership team, closed its first full quarter with Sanity Group in the fold, and, in CEO James Yamanaka's words, "sharpened our strategy for the years ahead." Translation: Canada's number-one cannabis company by market share is now trying to explain how it becomes a global one.

The lineup reflects that shift. Yamanaka and CFO Greg Guyatt will present alongside Finn Age Hänsel, the newly appointed President, Rest of World and Chief Strategy Officer, who came over with Sanity and now runs everything outside Canada. Expect updates from the production floor, a walk through growth priorities, and a fireside Q&A built from investor-submitted questions.

The timing isn't accidental. Organigram just reported record Q3 net revenue of $105.8 million, up 49%, and last month announced an accelerated Sanity integration under a unified global structure. With Curaleaf chasing Aurora's European assets in a hostile bid, Organigram gets a clean stage to make the case that it's already the Canadian company with a real German medical platform.

Registration and question submission are open at organigram.ca/investor-day-2026.

📺 Trade To Black

Bids, Banks, and Understanding The Definition of Hemp | TTB Presented by Flowhub

• Aurora fights back: Aurora's Board unanimously urged shareholders to reject Curaleaf's hostile bid as inadequate, pointing to its debt-free balance sheet and $149 million in cash versus Curaleaf's over $1 billion in debt.

• Cresco takes Pennsylvania: Cresco Labs closed its $50 million acquisition of PharmaCann Penn, adding nine dispensaries and making it the state's number one medical retailer to go with its wholesale lead.

• Banks are finally paying attention: Safe Harbor Financial CEO Terry Mendez returns with what banks are saying post-rescheduling, from 280E's disappearance to opportunity zone implications.

• What is hemp, really? Realm of Caring's Sasha Kalcheff-Korn breaks down the gap between hemp's legal definition and how consumers actually understand and use these products.